List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
Bioprojet SCR
Chrysalis Pharma SAS
JW Pharmaceutical Corp
Novartis AG
Sensorion SA
Sosei Heptares
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
adriforant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azasetron - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones
Featured News & Press Releases
Mar 16, 2020: Covid-19: Sensorion delays Phase ll trial due to slow recruitment rate
Feb 18, 2020: Sensorion gets approval to add new sites to Phase II trial of SENS-401
Feb 03, 2020: Sensorion to attend and present at LSX World Congress 2020
Jan 30, 2020: Sensorion presents new SENS-401 preclinical data at ARO Midwinter Meeting 2020
Jan 10, 2020: Sensorion announces its presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
Dec 23, 2019: Sensorion announces positive data safety monitoring board review of Phase 2 trial for SENS-401 in Sudden Sensorineural Hearing Loss
Dec 23, 2019: Sensorion announces €5.6m non-dilutive funding to support SENS-401 Phase 2 study in Sudden Sensorineural Hearing Loss French ministry of armed forces to participate in the study
Nov 20, 2019: Drug tested for sudden hearing loss
Nov 07, 2019: Sensorion announces an oral presentation of new SENS-401 preclinical data at ISIET 2019 in Hannover
Oct 23, 2019: Sensorion announce collaboration announces a poster presentation of new SENS-401 preclinical data at SFN 2019 in Chicago
Sep 11, 2019: Sensorion announces three presentations at IEB 2019 in Padua
Aug 27, 2019: LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
Jul 11, 2019: Sensorion receives FDA IND Approval for Arazasetron (SENS-401)
Jun 28, 2019: Sensorion’s PIP is EMA-approved for two indications
Mar 31, 2019: JW Pharmaceutical receives the Technology Export Award of the 20th Republic of Korea New Drug Development Awards
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Bioprojet SCR, H1 2020
Pipeline by Chrysalis Pharma SAS, H1 2020
Pipeline by JW Pharmaceutical Corp, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Sensorion SA, H1 2020
Pipeline by Sosei Heptares, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020

List of Figures
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

Companies Mentioned
• Bioprojet SCR
• Chrysalis Pharma SAS
• JW Pharmaceutical Corp
• Novartis AG
• Sensorion SA
• Sosei Heptares